EpiCast Report: Gastric Cancer Epidemiology Forecast to 2024
Summary
Gastric cancer, also called stomach cancer, is a multifactorial disease that starts in the tissues lining the stomach. Gastric cancer usually begins in cells in the inner layer of the stomach and tends to develop slowly into the outer layer over many years. In the early stages of gastric cancer, the affected individuals exhibit symptoms such as indigestion and stomach discomfort that require little medical attention and therefore, most of the cases remain undetected at the initial stages of the disease. Gastric cancer typically affects elderly individuals, ages 55 years and older, and peaks in the seventh decade of life and is twice as common in men as in women.
In 2014, there were a total of 312,520 diagnosed incident cases of gastric cancer in the 8MM. GlobalData epidemiologists forecast that the diagnosed incident cases of gastric cancer in the 8MM will increase to 364,518 cases by 2024 at an Annual Growth Rate (AGR) of 1.66%. In the 8MM, urban China had the highest number of diagnosed incident cases (134,968 cases) in 2014, and is expected to grow to 177,015 cases by 2024 at a high AGR of 3.12%.
GlobalData epidemiologists forecast for gastric cancer is supported by at least 10 years of historical data obtained from international cancer organizations, country-specific government sources, and peer-reviewed studies. The forecast of incident gastric cancer cases were based on detailed age-specific and sex-specific trends in incidence in each of the 8MM. This forecast provides detailed case-segmentation of the gastric cancer patient pool for each country by age, sex, and stage at diagnosis. Additionally, GlobalDatas analysis provides diagnosed incident cases of GEJ cancer and segmentation of diagnosed gastric cancer incident cases by cellular type and HER2 status. The forecast is driven by a thorough analysis of historical data. The forecast methodology was also consistent across all the 8MM, thereby allowing for a meaningful comparison of the forecast diagnosed incident and five-year diagnosed prevalent cases of gastric cancer across the 8MM.
Scope
The Gastric Cancer EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for gastric cancer in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and urban China). It includes a 10-year epidemiological forecast of the diagnosed incident cases of gastric cancer, gastroesophageal junction cancer, gastric adenocarcinoma, and the five-year diagnosed prevalent cases of gastric cancer segmented by age and sex in these markets. In addition this report provides further segmentation of gastric cancer by stage at diagnosis, cellular type, and human epidermal growth factor receptor status.
The gastric cancer epidemiology report is written and developed by Mastersand PhD-level epidemiologists.
The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
Reasons to buy
The Gastric Cancer EpiCast series will allow you to
Develop business strategies by understanding the trends shaping and driving the global gastric cancer market.
Quantify patient populations in the global gastric cancer market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for gastric cancer therapeutics in each of the markets covered.
Table Of Contents
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Related Reports 9
3 Epidemiology 10
3.1 Disease Background 10
3.2 Risk Factors and Comorbidities 11
3.3 Global Trends 12
3.3.1 8MM, Incidence Trends 13
3.4 Forecast Methodology 15
3.4.1 Sources Used 22
3.4.2 Sources Not Used 30
3.4.3 Forecast Assumptions and Methods, Diagnosed Incident Cases of Gastric Cancer — 8MM 31
3.4.4 Forecast Assumptions and Methods, Five-Year Diagnosed Prevalent Cases of Gastric Cancer — 8MM 31
3.4.5 Forecast Assumptions and Methods, Gastric Cancer Clinical Stages at Diagnosis — 8MM 32
3.4.6 Forecast Assumptions and Methods, Gastric Cancer Cellular Types — 8MM 34
3.4.7 Forecast Assumptions and Methods, HER2 Status — 8MM 35
3.4.8 Forecast Assumptions and Methods, Diagnosed Incident Cases of GEJ Cancer — 8MM 37
3.4.9 Forecast Assumptions and Methods, Diagnosed Incident Cases of Gastric Adenocarcinomas — 8MM 38
3.5 Epidemiological Forecast of Gastric Cancer (2014-2024) 39
3.5.1 Diagnosed Incident Cases of Gastric Cancer 39
3.5.2 Age-Specific Diagnosed Incident Cases of Gastric Cancer 41
3.5.3 Sex-Specific Diagnosed Incident Cases of Gastric Cancer 42
3.5.4 Age-Standardized Diagnosed Incidence of Gastric Cancer 44
3.5.5 Percentage Distribution of Diagnosed Incident Cases of Gastric Cancer, by Stage at Diagnosis 46
3.5.6 Percentage Distribution of Diagnosed Incident Cases of Gastric Cancer, by Cellular Type 47
3.5.7 Diagnosed Incident Cases of Gastric Cancer by HER2 Status 47
3.5.8 Diagnosed Incident Cases of GEJ Cancer 49
3.5.9 Five-Year Diagnosed Prevalent Cases of Gastric Cancer 51
3.6 Discussion 52
3.6.1 Epidemiological Forecast Insight 52
3.6.2 Limitations of the Analysis 53
3.6.3 Strengths of the Analysis 54
4 Appendix 55
4.1 Bibliography 55
4.2 About the Authors 60
4.2.1 Epidemiologists 60
4.2.2 Reviewers 60
4.2.3 Global Director of Therapy Analysis and Epidemiology 61
4.2.4 Global Head of Healthcare 62
4.3 About GlobalData 63
4.4 About EpiCast 63
4.5 Disclaimer 64
List Of Tables
1.1 List of Tables
Table 1: Risk Factors and Comorbidities for Gastric Cancer 12
Table 2: 8MM, Sources of Gastric Cancer Incidence Data 16
Table 3: 8MM, Sources Used in the Epidemiology Forecast for the Five-Year Diagnosed Prevalent Cases of Gastric Cancer 17
Table 4: 8MM, Sources of Gastric Cancer Stage at Diagnosis According to AJCC, TNM (Tumor, Node, Metastasis) Staging Manual 18
Table 5: 8MM, Sources of Distribution of Gastric Cancer Cases at Diagnosis by Cellular Type 19
Table 6: 8MM, Sources of GEJ Cancer Incidence Data 20
Table 7: 8MM, Sources of HER2-Positive Status in Diagnosed Incident Cases of Gastric Cancer 21
Table 8: 8MM, Diagnosed Incident Cases of Gastric Cancer, Both Sexes, Ages ?20 Years, N, 2014-2024 40
Table 9: 8MM, Age-Specific Diagnosed Incident Cases of Gastric Cancer, Both Sexes, N (Row %), 2014 41
Table 10: 8MM, Sex-Specific Diagnosed Incident Cases of Gastric Cancer, Ages ?20 Years, N (Row %), 2014 43
Table 11: 8MM, Diagnosed Incident Cases of Gastric Cancer, by HER2 Status, Both Sexes, Ages ?20 Years, N (Row %), 2014 48
Table 12: 8MM, Diagnosed Incident Cases of GEJ Cancer, Both Sexes, Ages ?20 Years, N, 2014-2024 50
Table 13: 8MM, Five-Year Diagnosed Prevalent Cases of Gastric Cancer, Both Sexes, Ages ?20 Years, N, 2014-2024 51
List Of Figures
1.2 List of Figures
Figure 1: 8MM, Age-Adjusted Gastric Cancer Incidence (Cases per 100,000 Population), Men, 1998-2007 14
Figure 2: 8MM, Age-Adjusted Gastric Cancer Incidence (Cases per 100,000 Population), Women, 1998-2007 14
Figure 3: 8MM, Diagnosed Incident Cases of Gastric Cancer, Both Sexes, Ages ?20 Years, N, 2014-2024 40
Figure 4: 8MM, Age-Specific Diagnosed Incident Cases of Gastric Cancer, Both Sexes, N, 2014 42
Figure 5: 8MM, Sex-Specific Diagnosed Incident Cases of Gastric Cancer, Ages ?20 Years, 2014 44
Figure 6: 8MM, Age-Standardized Diagnosed Incidence of Gastric Cancer (Cases per 100,000 Population), Ages ?20 Years, by Sex, 2014 45
Figure 7: 8MM, Percentage Distribution of Diagnosed Incident Cases of Gastric Cancer, by Stage at Diagnosis, Both Sexes, Ages ?20 Years 46
Figure 8: 8MM, Percentage Distribution of Diagnosed Incident Cases Gastric Cancer, by Cellular Type, Both Sexes, Ages ?20 Years 47
Figure 9: 8MM, Diagnosed Incident Cases of Gastric Cancer, by HER2 Status, Both Sexes, Ages ?20 Years, %, 2014 49
Figure 10: 8MM, Diagnosed Incident Cases of GEJ Cancer, Both Sexes, Ages ?20 Years, N, 2014-2024 50
Figure 11: 8MM, Five-Year Diagnosed Prevalent Cases of Gastric Cancer, Both Sexes, Ages ?20 Years, N, 2014-2024 52
